Immunomodulation with low dose levamisole in patients with colonic polyps

Moertel, 1990, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, New Engl J Med, 322, 352, 10.1056/NEJM199002083220602 Laurie, 1989, Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil, J Clin Oncol, 7, 1447, 10.1200/JCO.1989.7.10.1447 Holcombe, 1994, Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil, Cancer Immunol Immunother, 34, 394, 10.1007/BF01517209 DeBrander, 1995, Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU, Anticancer Res, 15, 2271 Janik, 1993, Dose-related immunologic effects of levamisole in patients with cancer, J Clin Oncol, 11, 125, 10.1200/JCO.1993.11.1.125 Clarke, 1997, The antitumor effect of levamisole in mice are mediated by NC-1.1+ cells, Cancer Immunol Immunother, 45, 115, 10.1007/s002620050410 Goodrich, 1993, Effect of levamisole on major histocompatibility complex (MHC) class I expression in colorectal and breast carcinoma cell lines, Cancer, 72, 225, 10.1002/1097-0142(19930701)72:1<225::AID-CNCR2820720140>3.0.CO;2-Y Kimball, 1996, Levamisole effects on major histocompatibility complex and adhesion molecule expression and on myeloid cell adhesion to human colon tumor cell lines, J Natl Cancer Inst, 88, 109, 10.1093/jnci/88.2.109 Holcombe, 1997, Augmentation of IL12-dependent Th1 cytokine production by levamisole, Allergy Clin Immunol Int, 9, 119 Holcombe, 2001, Investigating immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints, Cancer Detect Prev, 25, 183 Biological therapies for cancer: questions and answers in NCI on-line, August 16, 2004. http://cis.nci.nih.gov/fact/7_2.htm. Cancer facts and figures, 2004 at American Cancer Society Inc., 2004. http://www.cancer.org/. Jacobson-Brown, 2003, Colon polyps and cytokines: emerging immunological mechanisms, Rom J Gastroenterol, 12, 207 Robbins, 1991, Lymphocytopenia, T-lyphocyte subsets, and colorectal polyps in automotive pattern and model markers, J Occup Med, 33, 510 Murphy, 2002, The lineage decisions of helper T-cells, Nat Rev Immunol, 2, 933, 10.1038/nri954 Dredge, 2002, Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy, Cancer Immunol Immunother, 51, 521, 10.1007/s00262-002-0309-z Smyth, 2000, Differential tumor surveillance by natural killer (NK) and NKT-cells, J Exp Med, 191, 661, 10.1084/jem.191.4.661 Martiniello, 1996, Ly-6C+ natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of mice, Int J Cancer, 66, 532, 10.1002/(SICI)1097-0215(19960516)66:4<532::AID-IJC18>3.0.CO;2-9 Gozzo, 1979, Varied in vivo properties of levamisole (LMS) on the immune response in mice, Transpl Proc, 11, 1420 Bliznakov, 1977, Immunostimulation or immunodepression?, Biomedicine, 26, 73 Holcombe, 1999, Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest oncology group protocol 9009, Cancer Immunol Immunother, 48, 533, 10.1007/s002620050602 Block, 2002, The immune system in cancer, Integr Cancer Ther, 1, 294, 10.1177/153473540200100314